Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Total Non-Current Liabilities (2022 - 2025)

Atara Biotherapeutics' Total Non-Current Liabilities history spans 4 years, with the latest figure at $56.9 million for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities fell 71.97% year-over-year to $56.9 million; the TTM value through Dec 2025 reached $56.9 million, down 71.97%, while the annual FY2025 figure was $56.9 million, 71.97% down from the prior year.
  • Total Non-Current Liabilities reached $56.9 million in Q4 2025 per ATRA's latest filing, down from $65.0 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $259.2 million in Q1 2024 to a low of $56.9 million in Q4 2025.
  • Average Total Non-Current Liabilities over 4 years is $182.3 million, with a median of $213.5 million recorded in 2024.
  • Peak YoY movement for Total Non-Current Liabilities: surged 35.23% in 2023, then tumbled 71.97% in 2025.
  • A 4-year view of Total Non-Current Liabilities shows it stood at $244.2 million in 2022, then fell by 5.96% to $229.7 million in 2023, then decreased by 11.56% to $203.1 million in 2024, then crashed by 71.97% to $56.9 million in 2025.
  • Per Business Quant, the three most recent readings for ATRA's Total Non-Current Liabilities are $56.9 million (Q4 2025), $65.0 million (Q3 2025), and $70.2 million (Q2 2025).